Comparison of effects of CH50 on macrophage activation and its anti-tumor activity with those of lipopolysaccharides.
To investigate the characterization of pharmacological action & of CH50, a recombinant polypeptide of human fibronectin, by comparing the effects of CH50 on macrophage activation and its anti-tumor activity with those of lipopolysaccharides (LPS). The production of nitric oxide (NO) as an index macrophage activation was determined by colorimetric assay. The interferon-gamma (IFN-gamma) transfection was performed with coprecipitation of calcium phosphate and DNA. The melanoma B16 cells were inoculated into abdominal cavity of mice and the number of tumor nodes was recorded. At lower concentrations or when given alone in vitro, CH50 produced ten times less NO than LPS (P < 0.01). But at concentrations higher than 1 mg.L-1, CH50 activated the IFN-gamma-primed macrophages to produce NO to the same extent as LPS (P > 0.05). There was no synergism between CH50 and LPS. Both CH50 and LPS alone could reduce the number of tumor nodes in abdominal cavity of mice but CH50 had a stronger inhibitory effect on the growth of tumor in vivo as compared to LPS (P < 0.01). CH50/IFN-gamma had also a better inhibitory effect on tumor growth in vivo than LPS/IFN-gamma did. In the presence of IFN-gamma, the ability of CH50 to activate macrophages is the same as that of LPS. But CH50 has better antitumorogenic effects in vivo against mouse melanoma as compared to LPS.